Shopping Cart 0
Cart Subtotal
USD 0

Paratek Pharmaceuticals Inc (PRTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company's lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypical bacteria. It is investigating omadacycline in Phase III for the treatment of infections resistant to antibiotics: acute bacterial skin and skin structure infections (ABSSSI); community acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other community-acquired bacterial infections. The company is also developing sarecycline an oral, once-daily, antibiotic in Phase III for the treatment of acne and rosacea. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc (PRTK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Zai Lab Enters into Licensing Agreement with Paratek Pharma 11

Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12

Equity Offering 13

Paratek Pharma Raises USD50 Million in Public Offering of Shares 13

Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15

Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16

Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17

Paratek Pharma Raises USD76 Million in Public Offering of Shares 19

Paratek Pharma Raises USD93 Million in Private Placement 21

Paratek Pharma Withdraws IPO 23

Debt Offering 24

Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24

Acquisition 25

Paratek Pharma May Sell Itself 25

Transcept Pharma Acquires Paratek Pharma 27

Paratek Pharmaceuticals Inc-Key Competitors 29

Paratek Pharmaceuticals Inc-Key Employees 30

Paratek Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Strategy And Business Planning 32

Mar 24, 2017: Paratek Pharmaceuticals Opens New Office in King of Prussia 32

Financial Announcements 33

Nov 06, 2018: Paratek Pharmaceuticals reports third quarter 2018 financial results 33

Aug 02, 2018: Paratek Pharmaceuticals announces second quarter 2018 financial results 34

May 09, 2018: Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results 36

Mar 01, 2018: Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 37

Aug 02, 2017: Paratek Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical Update 38

May 04, 2017: Paratek Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical Update 39

Mar 02, 2017: Paratek Pharmaceuticals Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 40

Corporate Communications 41

Apr 13, 2018: Paratek Names Rolf K. Hoffman As Board Director 41

Oct 02, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c) 42

Aug 01, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 43

Jan 04, 2017: Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paratek Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Zai Lab Enters into Licensing Agreement with Paratek Pharma 11

Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12

Paratek Pharma Raises USD50 Million in Public Offering of Shares 13

Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15

Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16

Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17

Paratek Pharma Raises USD76 Million in Public Offering of Shares 19

Paratek Pharma Raises USD93 Million in Private Placement 21

Paratek Pharma Withdraws IPO 23

Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24

Paratek Pharma May Sell Itself 25

Transcept Pharma Acquires Paratek Pharma 27

Paratek Pharmaceuticals Inc, Key Competitors 29

Paratek Pharmaceuticals Inc, Key Employees 30

Paratek Pharmaceuticals Inc, Other Locations 31

Paratek Pharmaceuticals Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Paratek Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. Omadacycline (antibiotic), the company's lead product candidate is an aminomethylcycline which acts against gram-negative, gram-positive, and atypical bacteria. It is investigating omadacycline in Phase III for the treatment of infections resistant to antibiotics: acute bacterial skin and skin structure infections (ABSSSI); community acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other community-acquired bacterial infections. The company is also developing sarecycline an oral, once-daily, antibiotic in Phase III for the treatment of acne and rosacea. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc (PRTK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Zai Lab Enters into Licensing Agreement with Paratek Pharma 11

Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12

Equity Offering 13

Paratek Pharma Raises USD50 Million in Public Offering of Shares 13

Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15

Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16

Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17

Paratek Pharma Raises USD76 Million in Public Offering of Shares 19

Paratek Pharma Raises USD93 Million in Private Placement 21

Paratek Pharma Withdraws IPO 23

Debt Offering 24

Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24

Acquisition 25

Paratek Pharma May Sell Itself 25

Transcept Pharma Acquires Paratek Pharma 27

Paratek Pharmaceuticals Inc-Key Competitors 29

Paratek Pharmaceuticals Inc-Key Employees 30

Paratek Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Strategy And Business Planning 32

Mar 24, 2017: Paratek Pharmaceuticals Opens New Office in King of Prussia 32

Financial Announcements 33

Nov 06, 2018: Paratek Pharmaceuticals reports third quarter 2018 financial results 33

Aug 02, 2018: Paratek Pharmaceuticals announces second quarter 2018 financial results 34

May 09, 2018: Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results 36

Mar 01, 2018: Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 37

Aug 02, 2017: Paratek Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical Update 38

May 04, 2017: Paratek Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical Update 39

Mar 02, 2017: Paratek Pharmaceuticals Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 40

Corporate Communications 41

Apr 13, 2018: Paratek Names Rolf K. Hoffman As Board Director 41

Oct 02, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c) 42

Aug 01, 2017: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 43

Jan 04, 2017: Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Paratek Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Paratek Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Zai Lab Enters into Licensing Agreement with Paratek Pharma 11

Paratek Pharma Enters into Agreement with US Army Medical Research Institute of Infectious Diseases 12

Paratek Pharma Raises USD50 Million in Public Offering of Shares 13

Paratek Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 15

Paratek Pharma Plans to Raise up to USD50 Million in Public Offering 16

Paratek Pharma Raises USD63.53 Million in Public Offering of Shares 17

Paratek Pharma Raises USD76 Million in Public Offering of Shares 19

Paratek Pharma Raises USD93 Million in Private Placement 21

Paratek Pharma Withdraws IPO 23

Paratek Pharma Raises USD140 Million in Private Placement of Notes Due 2024 24

Paratek Pharma May Sell Itself 25

Transcept Pharma Acquires Paratek Pharma 27

Paratek Pharmaceuticals Inc, Key Competitors 29

Paratek Pharmaceuticals Inc, Key Employees 30

Paratek Pharmaceuticals Inc, Other Locations 31

Paratek Pharmaceuticals Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Paratek Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.